医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mannatech Announces 100th Patent

2015年02月11日 PM08:00
このエントリーをはてなブックマークに追加


 

COPPELL, Texas

Mannatech, Incorporated (NASDAQ:MTEX), the founder of the M5MSM (Mission 5 MillionSM) social entrepreneurial movement, the pioneer of nutritional glycobiology and the global innovator of naturally sourced supplements based on Real Food Technology® solutions, has been issued its 100th patent, demonstrating its commitment to delivering and protecting its unique formulations in major global markets.

Mannatech receiving 100 patents is an exceptional accomplishment for a company in the nutritional supplement industry. Mannatech, compared to many of its competitors, invests heavily in a robust research and development program to create its unique technology and formulations. With many of its formulations patented in multiple major global markets, Mannatech can exclude others from exploiting certain Mannatech patents and provide its customers with high value, quality products that stand out in the nutritional supplement crowd.

“It is uncommon for a company in this industry to have even one patent,” said Dr. Rob Sinnott, CEO and Chief Science Officer at Mannatech. “Mannatech commits a great deal of resources, time and funding into the patent process in major global markets to ensure our unique technologies are recognized, validated and protected.”

The company’s 100th patent was issued in Korea for its PhytoMatrix® product, an all-natural multivitamin and multimineral dietary supplement formulation.

“This 100-patent milestone shows Mannatech’s concerted effort to keep its products from becoming mere commodities in the nutritional supplement market,” said Sinnott. “We closely guard our core technology and formulations with patents, which makes our products far more valuable. We believe this approach helps our Associates to build a successful business in major global markets around the world.”

The Certificate of Grant for Mannatech’s PhytoMatrix formulation in Korea was received on Nov. 18, 2014, just 11 days after the 99th company patent was issued for the PhytoMatrix formulation in Japan on Nov. 7, 2014. The patent will remain in effect for 20 years from the date of filing. There are now eight patents issued in major global markets to Mannatech regarding the PhytoMatrix technology. Overall, 100 patents have been issued, granted and validated in major global markets to the company for the technology pertaining to its Ambrotose®, Ambrotose AO®, GI-ProBalance®, and PhytoMatrix product formulations and in the field of biomarker assays.

Mannatech’s unique PhytoMatrix formulation has been on the market since 2006. It is one of the few vitamin and mineral supplements available that contains minerals from hydroponically grown Indian Mustard plant and food-sourced vitamins and phytonutrients from fruits and vegetables. PhytoMatrix is gluten-free and suitable for vegetarian diets.

Mannatech has a thorough, industry-leading quality assurance program that complies with the U.S. Food and Drug Administration’s current Good Manufacturing Practices for dietary supplements, which impact all aspects of product development, manufacturing, evaluation, storage and distribution. Additionally, many of Mannatech’s products feature third-party certification through NSF International. NSF certification assures that a number of Mannatech products, including PhytoMatrix, have been rigorously tested and comply with requirements such as accurate labeling and purity standards.

A number of Mannatech’s broad portfolio of patented products has been validated by research conducted by independent scientists and published in peer-reviewed scientific journals. Currently, 17 human clinical trials have been published, 13 of which were double-blind, placebo-controlled studies – the gold standard for product validation.

Individuals interested in Mannatech’s products can learn more at Mannatech.com. Those interested in obtaining technical information and reading published product studies may visit MannatechScience.org.

About Mannatech

Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech’s proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico, Namibia, Spain and Hong Kong. For more information, visit Mannatech.com.

Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150211005157/en/

CONTACT

Mannatech, Incorporated
Raquel Mooring, 972-471-1532
rmooring@mannatech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表